학술논문
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Document Type
Article
Author
Motzer, Robert J ; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M; Kessler, Elizabeth R; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Apolo, Andrea B; Choueiri, Toni K
Source
In The Lancet Oncology July 2022 23(7):888-898
Subject
Language
ISSN
1470-2045